Sofosbuvir May be a Potential Anti-SARS-CoV-2 RdRp Drug
Mohamed Nabil Ibrahim1 & Abdo Abdellah Elfiky2 Show affiliations
- Jouf University, Saudi Arabia
- Cairo University, Egypt
American Journal of Biochemistry and Biotechnology, Volume 17, Issue 2, pp. 205–207 · doi.org/10.3844/ajbbsp.2021.205.207
Abstract
The Coronavirus Diseases 2019 (COVID-19) seriously affecting human health all over the world. More than 107 M people are reported positive for SARS-CoV-2, the virus causing COVID-19 pneumonia, from which +2.3 M died. Nucleotide Inhibitors (NI) have promising results in terms of its efficacy against different viral polymerases, including the Hepatitis C Virus (HCV) Non-Structural Protein 5 B (NS5B) RNA dependent RNA polymerase (RdRp) 1. Thus, the non-structural protein 12 (nsp12) RdRp of the human coronavirus represents an attractive target to develop a possible therapeutic agent. Sofosbuvir proved itself as a potential anti-SARS-CoV-2 RdRp and could inhibit viral replication and infection propagation.
Licence and reuse
Open access. This article is licensed under a Creative Commons Attribution 4.0 International Licence (CC BY 4.0), as printed on the article, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original authors and the source. No permission is needed.
How to reuse this articleResponses (0)
About this article
Ibrahim, M. N. & Elfiky, A. A. (2021). Sofosbuvir May be a Potential Anti-SARS-CoV-2 RdRp Drug. American Journal of Biochemistry and Biotechnology, 17(2), 205–207. https://doi.org/10.3844/ajbbsp.2021.205.207
- Licence
- CC BY 4.0
- Issue
- Volume 17, Issue 2
- Policies
- Editorial independenceUse of generative AIData availabilityAppeals and complaints
- Version
- Version of record